<DOC>
	<DOCNO>NCT03064763</DOCNO>
	<brief_summary>No formal statistical hypothesis test safety endpoint trial . Based well tolerated safety profile global phase 3 study , hypothesize talimogene laherparepvec safe well tolerate Japanese subject unresectable Stage IIIB-IVM1c melanoma . A DRR hypothesize consistent result global phase 3 study</brief_summary>
	<brief_title>Study Evaluate Safety/ Efficacy T-VEC Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirm diagnosis melanoma Subject stage IIIB IVM1c melanoma surgically resectable Subject treatment naive determine physician suitable eligible approve systemic anticancer drug therapy Japan . Subject may also receive prior systemic anticancer treatment consist chemotherapy , immunotherapy , target therapy . Treatment melanoma must complete least 28 day prior enrollment . Candidate intralesional therapy ( ie , disease appropriate direct injection use ultrasound guidance , appropriate ) define one following : least 1 injectable cutaneous , subcutaneous , nodal melanoma lesion great equal 10 mm long diameter , OR multiple injectable melanoma lesion aggregate long diameter great equal 10 mm Measurable disease define one following : least 1 melanoma lesion accurately serially measure least 2 dimension greatest diameter great equal 10 mm measure contrastenhanced spiral compute tomography ( CT ) scan , magnetic resonance imaging ( MRI ) , ultrasound nodal/soft tissue disease ( include lymph node ) least 1 great equal to10 mm long diameter superficial cutaneous subcutaneous melanoma lesion measure caliper multiple superficial melanoma lesion aggregate total diameter great equal 10 mm Serum lactate dehydrogenase ( LDH ) level less equal 1.5 X upper limit normal ( ULN ) within 28 day prior enrollment Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Other Inclusion Criteria May Apply . Clinically active cerebral metastasis . Subjects 3 cerebral metastasis may enrol , provide lesion adequately treat stereotactic radiation therapy ( include Gamma Knife ) craniotomy , evidence progression require steroid least 2 month prior enrollment . Greater 3 visceral metastasis ( include lung metastasis nodal metastasis associated visceral organ ) . For subject le equal 3 visceral metastasis , lesion great 3 cm long dimension liver lesion must stable least 1 month prior enrollment . Bone metastases Primary ocular mucosal melanoma History evidence symptomatic autoimmune disease ( eg , pneumonitis , glomerulonephritis , vasculitis , ) , history autoimmune disease require systemic treatment ( ie , use corticosteroid , immunosuppressive drug biological agent use treatment autoimmune disease ) past 2 month prior enrollment . Active herpetic skin lesion prior complication herpetic infection ( eg , herpetic keratitis encephalitis ) . Requires intermittent chronic systemic ( intravenous oral ) treatment antiherpetic drug ( eg , acyclovir ) , intermittent topical use . Previous treatment talimogene laherparepvec Other investigational procedure participate study exclude . Known acute chronic active hepatitis B infection , acute chronic active hepatitis C infection human immunodeficiency virus ( HIV ) infection Subject know sensitivity bovine porcine derive component product component administer dose . History malignancy within past 3 year Other Exclusion Criteria May Apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Unresectable Stage IIIB-IV Malignant Melanoma</keyword>
</DOC>